magazinelogo

International Journal of Clinical and Experimental Medicine Research

ISSN Print: 2575-7989 Downloads: 226102 Total View: 2534955
Frequency: quarterly ISSN Online: 2575-7970 CODEN: IJCEMH
Email: ijcemr@hillpublisher.com
Article Open Access http://dx.doi.org/10.26855/ijcemr.2023.01.008

Circular RNA Circ_0001971 Aggravates the Progression of Hepatocellular Carcinoma Cells by Activating the miR-186-5p/KLF7

Cong Zeng

The People's Hospital of Guizhou Province, Guizhou 550002, China.

*Corresponding author: Cong Zeng

Published: February 6,2023

Abstract

Background: Circ_0001971 has been shown to play an important role in cancer development, yet its mechanism of action in hepatocellular carcinoma (HCC) remains somewhat unknown. Methods: RNA sequence analysis was performed on HCC tissues and paired non-tumor tissues to detect differentially expressed Rnas. qPCR was used to detect the expression level of circ_0001971. CCK-8, Transwell, RNA immunoprecipitation experiment, WB detection, Double luciferase reporter gene assay et al. were used to analyze the interaction between circ_0001971 and miR-186-5p/KLF7. Results: Circ_0001971 expression was significantly upregulated in HCC cells; circ_0001971 inhibition significantly inhibited proliferation, migration and invasion of HCC cells (P<0.05); miR-186-5p was a downstream target of circ_0001971; KLF7 was a target gene of miR-186-5p; circ_0001971 can indirectly positively regulate KLF7. Conclusions: Circ_0001971 aggravates HCC progression by activating miR-186-5p/KLF7.

References

[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA: a cancer journal for clinicians, 2021, 71(3): 209-249.

[2] WHITE D L, THRIFT A P, KANWAL F, et al. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012 [J]. Gastroenterology, 2017, 152( 4) : 812-820

[3] Zhou WY, Cai ZR, Liu J, et al. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020; 19(1):172.

[4] Chen KH, Pan JF, Chen ZX, et al. Effects of hsa_circ_0000711 expression level on proliferation and apoptosis of hepatoma cells [J]. Eur Rev Med Pharmacol Sci, 2020, 24(8): 4161-4171.

[5] Tan X, Zhou C, Liang Y, Lai YF, Liang Y. Circ_0001971 regulates oral squamous cell carcinoma progression and chemosensitivity by targeting miR-194/miR-204 in vitro and in vivo. Eur Rev Med Pharmacol Sci. 2020 Mar; 24(5):2470-2481.

[6] Han TS, Hur K, Cho HS, et al. Epigenetic associations between lncRNA/circRNA and miRNA in hepatocellular carcinoma. Cancers (Basel). 2020; 12(9):2622.

[7] Shen Xingjie, Zhu Xiaoyan, Hu Peixin, Ji Tingting, Qin Ying, Zhu Jingyu. Knockdown circZNF131 Inhibits Cell Progression and Glycolysis in Gastric Cancer Through miR-186-5p/PFKFB2 Axis [J]. Biochemical genetics, 2022 (prepublish).

[8] Gao Ming, Liu Liying, Yang Yudan, Li Mengyi, Ma Qingqing, Chang Zhiwei. LncRNA HCP5 Induces Gastric Cancer Cell Proliferation, Invasion, and EMT Processes Through the miR-186-5p/WNT5A Axis Under Hypoxia [J]. Frontiers in cell and developmental biology, 2021, 9.

[9] Liu Yanhong, Jiang Yuanyuan, Xu Lidong, Qu Chongxing, Zhang Lei, Xiao Xingguo, Chen Wenxia, Li Kunkun, Liang Qianping, Wu Huili. circ-NRIP1 Promotes Glycolysis and Tumor Progression by Regulating miR-186-5p/MYH9 Axis in Gastric Cancer [J]. Cancer management and research, 2020, 12(default).

[10] Guo Junfeng, Wang Xingyu, Guo Qingdong, Zhu Shengtao, Li Peng, Zhang Shutian, Min Li. M2 Macrophage Derived Extra-cellular Vesicle-Mediated Transfer of MiR-186-5p Promotes Colon Cancer Progression by Targeting DLC1 [J]. International journal of biological sciences, 2022, 18(4).

[11] Farhadul Islam, Vinod Gopalan, Jelena Vider, Riajul Wahab, Faeza Ebrahimi, Cu-tai Lu, Kais Kasem, Alfred K.Y. Lam. MicroRNA-186-5p overexpression modulates colon cancer growth by repressing the expression of the FAM134B tumour in-hibitor [J]. Experimental Cell Research, 2017, 357(2).

[12] Liu X, Zhou X, Chen Y, Huang Y, He J, Luo H. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs) [J]. Neoplasma, 2020, 67(1).

[13] Das BK. Altered Gut Microbiota in Hepatocellular Carcinoma: Insights into the Pathogenic Mechanism and Preclinical to Clinical Findings. APMIS. 2022 Nov 2.

[14] Wang X, Zhang J, Luo F, Shen Y. Application of CircRNA Circ_0071662 in the diagnosis and prognosis of hepatocellular carcinoma and its response to radiotherapy. Dig Dis. 2022 Oct 24.

[15] Han Q, Wang M, Dong X, Wei F, Luo Y, Sun X. Non-coding RNAs in hepatocellular carcinoma: Insights into regulatory mechanisms, clinical significance, and therapeutic potential. Front Immunol. 2022 Oct 10; 13:985815.

[16] Chen J, Qi Z. The Elevated Circ_0067835 Could Accelerate Cell Proliferation and Metastasis via miR-1236-3p/Twist2 Axis in Hepatocellular Carcinoma. Biomed Res Int. 2022 Oct 10; 2022:2825172.

[17] Li CM, Wu W, Zhu Z, Lu PL, Gong JP, Ma R. miR-550a-5p promotes the proliferation and migration of hepatocellular carcinoma by targeting GNE via the Wnt/β-catenin signaling pathway. Neoplasma. 2022 Nov 11:220727N774.

[18] Jin C, Zhao W, Zhang Z, Liu W. Silencing circular RNA circZNF609 restrains growth, migration and invasion by up-regulating microRNA-186-5p in prostate cancer. Artif Cells Nanomed Biotechnol. 2019 Dec; 47(1):3350-3358.

[19] Orzechowska-Licari EJ, LaComb JF, Mojumdar A, Bialkowska AB. SP and KLF Transcription Factors in Cancer Metabolism. Int J Mol Sci. 2022 Sep 1; 23(17):9956.

[20] Long J, Liu L, Yang X, Zhou X, Lu X, Qin L. LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway. Hum Cell. 2022 Oct 15.

How to cite this paper

Circular RNA Circ_0001971 Aggravates the Progression of Hepatocellular Carcinoma Cells by Activating the miR-186-5p/KLF7

How to cite this paper: Cong Zeng. (2023) Circular RNA Circ_0001971 Aggravates the Progression of Hepatocellular Carcinoma Cells by Activating the miR-186-5p/KLF7. International Journal of Clinical and Experimental Medicine Research7(1), 43-48.

DOI: http://dx.doi.org/10.26855/ijcemr.2023.01.008